Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Depreciation & Amortization (CF) (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $75000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 2.6% year-over-year to $75000.0; the TTM value through Sep 2025 reached $303000.0, down 2.26%, while the annual FY2024 figure was $309000.0, 2.83% down from the prior year.
  • Depreciation & Amortization (CF) reached $75000.0 in Q3 2025 per BTAI's latest filing, roughly flat from $75000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $85000.0 in Q3 2022 and bottomed at $75000.0 in Q2 2025.
  • Average Depreciation & Amortization (CF) over 4 years is $78666.7, with a median of $78000.0 recorded in 2023.
  • The widest YoY moves for Depreciation & Amortization (CF): up 3.9% in 2023, down 7.06% in 2023.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $81000.0 in 2022, then fell by 3.7% to $78000.0 in 2023, then dropped by 1.28% to $77000.0 in 2024, then dropped by 2.6% to $75000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $75000.0 in Q3 2025, $75000.0 in Q2 2025, and $76000.0 in Q1 2025.